There are 2 new reports on the NICE Decision Support Unit (DSU) website that outline detailed analyses that were undertaken in support of two recent technology appraisals; prevention of osteoporotic fragility fractures in postmenopausal women and treatements for Alzheimer’s disease.
Comments on appraisal of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women examines the validity of the relative risk of strontium ranelate in reducing hip fracture risk as estimated by the manufacturer, Servier.
A review of the Eisai / Pfizer economic model on the cost-effectiveness of donepezil examines the manufacturers’ submission, which took the form of a discrete event simulation in a package not well known to Institute’s technology appraisal teams.
For further information, contact the Acting Director of the DSU, Paul Tappenden.
